Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

BIZARRE: Bsx | Mind Blowing Facts

Boston Scientific Stock: Is BSX Underperforming the Healthcare Sector?

Boston Scientific has considerably underperformed its sector peers recently, yet analysts remain highly optimistic about the stock’s prospects.

Barchart

Unusual Options Activity Points to Boston Scientific Stock as a Hot M&A Target

Boston Scientific posted two of the top three Volume-to-Open Interest ratios during Thursday's trading session, a notable signal often associated with heightened market speculation. This unusual options activity suggests the medical devices giant could be a potential acquisition target. Here's a closer look at why.

Barchart

Boston Scientific Stock: Is Wall Street Bullish or Bearish?

Boston Scientific has lagged behind the broader market over the past year, yet analysts remain highly bullish about the stock’s prospects.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

Massively Disappointing Boston Scientific (BSX) Stock Could Be Due for a Comeback

Although a seemingly inopportune acquisition appears to have cost Boston Scientific dearly, the current valuation of BSX stock may be too enticing to pass up.

Barchart

Boston Scientific's Q1 2026 Earnings: What to Expect

Boston Scientific is ready to announce its fiscal first-quarter earnings soon, and analysts project a single-digit earnings growth.

Barchart

Why Boston Scientific's Big Dip Could Be a Bigger Opportunity

Boston Scientific's pending trial results could help to drive sales growth for years to come after lower-than-expected sales forecasts.

MarketBeat

The Highest-Rated Healthcare Stock to Buy Now to Hedge Against Oil Price Shocks

Amid oil-driven volatility, investors lean on resilient sectors, with Boston Scientific Corporation now standing out as a steady defensive healthcare play.

Barchart

Read news from The Economist, FT, and more,
with one subscription

Don't Miss Out: Strangle Plays on These 3 Top 25 Unusually Active Options Gems!

There were 1,234 unusually active options on Wednesday. Among the top 25 Vol/OI ratios were three popular stocks: Peloton Interactive, Boston Scientific, and Uber Technologies. There’s an argument for both long and short strangles. Here’s why.

Barchart

Boston Scientific Stock: Analyst Estimates & Ratings

Though Boston Scientific has lagged behind the broader market over the past year, Wall Street analysts maintain a bullish outlook on the stock’s prospects.

Barchart

Boston Scientific Earnings Preview: What to Expect

Boston Scientific will release its fourth-quarter earnings next month, and analysts anticipate a low double-digit bottom-line growth.

Barchart

Is Boston Scientific Stock Underperforming the Nasdaq?

Boston Scientific has underperformed the Nasdaq over the past year, but analysts are highly optimistic about the stock’s prospects.

Barchart

Targa Resources, Take-Two Interactive, Boston Scientific: Why Experts Rate These Stocks at Strong Buy

Wall Street is highly bullish on these three high-quality stocks.

Kiplinger

Boston Scientific Delivers Robust Q3 Despite Tariff Headwinds: Analyst

On Wednesday, Boston Scientific Corporation (NYSE:BSX) reported third-quarter 2025 revenues of $5.07 billion, beating the consensus estimate of $4.97 billion.

Benzinga

These Analysts Increase Their Forecasts On Boston Scientific After Upbeat Earnings

Boston Scientific Corporation (NYSE:BSX) reported better-than-expected third-quarter results on Wednesday.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Boston Scientific Gains Momentum As Growth Broadens, Goldman Sachs Says

Boston Scientific Corp (NYSE:BSX) delivered "another set of strong top-line results," which trickled down to an earnings beat, according to Goldman Sachs.

Benzinga

Boston Scientific Jumps On Strong Guidance, Heart Devices Fuel Topline Growth

Boston Scientific Corporation (NYSE:BSX) reported third-quarter 2025 revenues of $5.07 billion on Wednesday, beating the consensus estimate of $4.97 billion.

MarketBeat

Beware the Death Cross: 3 Stocks Triggering This Spooky Signal

The Death Cross is something you never want to see on a stock you own. Take caution with these three companies that recently were visited by this scary signal.

Barchart

What You Need To Know Ahead of Boston Scientific's Earnings Release

Boston Scientific is poised to release its third-quarter results later this month, and analysts project a double-digit earnings growth.

Get all your
news in one place.

100's of premium titles.
One news app.

MarketBeat

3 Healthcare Stocks Using AI to Drive Growth

AI is reshaping healthcare by improving outcomes and easing burnout. See how three companies are leading this transformation

Barchart

Is Boston Scientific Stock Outperforming the S&P 500?

As Boston Scientific has outpaced the S&P 500 Index over the past year, analysts are strongly optimistic about the stock’s prospects.

MarketBeat

3 Biotech Catalysts Present Major Opportunity

Three promising biotech names stand out for potentially catalyzing drugs currently on the market or in development; here's why they may rally further.

Barchart

Boston Scientific Stock Outlook: Is Wall Street Bullish or Bearish?

Boston Scientific has outperformed the broader market over the past year, and analysts are highly optimistic about the stock’s prospects.

Barchart

How Unusual Options Standout Boston Scientific (BSX) is Signaling a Statistical Edge

BSX stock may extend its solid performance as options activity and historical patterns suggest a bullish setup with favorable short-term odds.

Barchart

What to Expect From Boston Scientific's Next Quarterly Earnings Report

Boston Scientific is set to announce its second-quarter results later this month, and analysts anticipate double-digit earnings growth.

Barchart

How Is Boston Scientific's Stock Performance Compared to Other Medical Device Stocks?

Due to Boston Scientific's strong performance relative to its industry peers over the past year, Wall Street analysts maintain a bullish outlook on the stock’s prospects.

1 2 3

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.